197 related articles for article (PubMed ID: 24761480)
1. [When injectable diabetes therapy becomes necessary. Insulin or GLP-1 analogs?].
Stiefelhagen P
MMW Fortschr Med; 2011 Jan; 153(1-2):14. PubMed ID: 24761480
[No Abstract] [Full Text] [Related]
2. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.
Carris NW; Taylor JR; Gums JG
Drugs; 2014 Dec; 74(18):2141-52. PubMed ID: 25414121
[TBL] [Abstract][Full Text] [Related]
3. Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists.
Charbonnel PB
Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S1-6S2. PubMed ID: 26774014
[No Abstract] [Full Text] [Related]
4. When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump.
Cohen O; Filetti S; Castañeda J; Maranghi M; Glandt M
Diabetes Care; 2016 Aug; 39 Suppl 2():S180-6. PubMed ID: 27440831
[TBL] [Abstract][Full Text] [Related]
5. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
Lane W; Weinrib S; Rappaport J
Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
[TBL] [Abstract][Full Text] [Related]
6. [Insulin therapy in type 2 diabetes].
Hummel M
MMW Fortschr Med; 2011 Jun; 153(23):56-9, 61; quiz 62. PubMed ID: 21688497
[No Abstract] [Full Text] [Related]
7. Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option.
Gómez-Huelgas R; Azriel S; Puig-Domingo M; Vidal J; de Pablos-Velasco P
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):230-40. PubMed ID: 25066229
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.
Tzefos M; Olin JL
Ann Pharmacother; 2010; 44(7-8):1294-300. PubMed ID: 20530705
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.
Huthmacher JA; Meier JJ; Nauck MA
Diabetes Care; 2020 Sep; 43(9):2303-2312. PubMed ID: 32910778
[TBL] [Abstract][Full Text] [Related]
10. Summaries for patients. Inhaled insulin with or instead of oral medications for type 2 diabetes.
Ann Intern Med; 2005 Oct; 143(8):I28. PubMed ID: 16230717
[No Abstract] [Full Text] [Related]
11. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
Owens DR; Monnier L; Bolli GB
Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
[TBL] [Abstract][Full Text] [Related]
12. Common patient concerns about the use of glucagon-like peptide-1 receptor agonists in diabetes mellitus management.
Freeman JS; Gavin JR; Spellman CW
J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S22-4. PubMed ID: 22267301
[TBL] [Abstract][Full Text] [Related]
13. Individualizing care with injectable glucose-lowering agents.
Miller EM
J Fam Pract; 2013 Dec; 62(12 Suppl CME):S12-9. PubMed ID: 24340344
[TBL] [Abstract][Full Text] [Related]
14. [Insulin therapy in patients with type 2 diabetes].
Siegmund T; Schumm-Draeger PM
MMW Fortschr Med; 2008 May; 150(18):32-5; quiz 36. PubMed ID: 18533606
[No Abstract] [Full Text] [Related]
15. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
[TBL] [Abstract][Full Text] [Related]
16. [A simple regimen only lasts a short time].
Einecke D
MMW Fortschr Med; 2007 Oct; 149(40):12-4. PubMed ID: 18018501
[No Abstract] [Full Text] [Related]
17. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
[TBL] [Abstract][Full Text] [Related]
18. 'For me, it didn't seem as drastic a step as being controlled by insulin': A qualitative investigation of expectations and experiences of non-insulin injectable therapy among adults with type 2 diabetes.
Holmes-Truscott E; Schipp J; Dunning T; Furler J; Hagger V; Holloway EE; Manski-Nankervis JA; Shaw JE; Skinner T; Speight J
Diabet Med; 2022 Feb; 39(2):e14681. PubMed ID: 34465005
[TBL] [Abstract][Full Text] [Related]
19. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
Fernández-García JC; Colomo N; Tinahones FJ
Med Clin (Barc); 2014 Sep; 143 Suppl 2():18-22. PubMed ID: 25437461
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.
Wang Y; Li L; Yang M; Liu H; Boden G; Yang G
Diabetes Obes Metab; 2011 Nov; 13(11):972-81. PubMed ID: 21651690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
